Source - RNS
RNS Number : 4711I
Quantum Pharma PLC
31 August 2016

For immediate release

31 August 2016


Quantum Pharma Plc

('Quantum' or the 'Group')



Trading Update

Notice of Half Year Results


Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, is pleased to announce its trading update for the half year ended 31 July 2016.


Quantum made good progress during the half year and the Board is pleased to announce that trading for the period was in line with management expectations.


During the period the Group launched a number of products from its Niche Pharmaceuticals division, particularly in the second quarter.  The timing of these product launches has been largely in line with our expectations and we are now moving into the market access and sales delivery phase in relation to those products.


The Vitamin D product portfolio was extended by launching Colecalciferol 800 IU capsules and 1000 IU capsules in both branded (Aviticol®) and generic versions, as well as Ergocalciferol 50 000 IU capsules.  In the past two months the Mucodis® range of in-licensed patented medical devices was completed by the launch of a further three Mucodis® products.


Since the period end, we have launched our licensed Glycopyrronium Bromide 1mg/5ml Oral Solution for the treatment of peptic ulcers.  This is significant in illustrating the deliverability of the Group's strategy of converting unlicensed to licensed products.


The Specials Division continues to be well placed in the market and traded in line with management expectations during the first half.  In April, we were pleased to extend our contract with AAH Pharmaceuticals, the UK's leading wholesaler and distributor of pharmaceutical and healthcare products, which is important for the Group financially and strategically.


The Board continues to expect the Group to meet market expectations for the full year to 31 January 2017.  As previously indicated, the Group's performance for the year is second-half weighted and will be dependent on the level of sales achieved by recent product launches as well as the timing and sales of further product launches due to be delivered in the remainder of the year.


Notice of Half Year Results


Quantum will announce its half year results for the six months ended 31 July 2016 on Tuesday, 4 October 2016.  A meeting for analysts will be held at 09.30 a.m. on the morning of the results, 4 October 2016, at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.  For further information please contact Buchanan at the details below.


- Ends -


  For further information:

Quantum Pharma Plc


Chris Rigg, Acting CEO and CFO

Tel: +44 (0) 1207 279 404

Craig Swinhoe, Group Corporate Affairs Director and Company Secretary



Zeus Capital Limited

(Nominated Adviser & Joint Broker)


Andrew Jones / Nick Cowles / Jamie Peel

Tel: +44 (0) 20 3829 5000

Dominic Wilson / John Goold



N+1 Singer

(Joint Broker)



Aubrey Powell / James White / Sandy Ritchie

Tel: +44 (0) 20 7496 3000

Nick Owen / Brough Ransom

Media enquiries:




Henry Harrison-Topham / Sophie Cowles / Steph Watson

Tel: +44 (0) 20 7466 5000

[email protected]



Notes to Editors


Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets.  Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.


Specials comprises four business units (Quantum Pharmaceutical, UL Medicines, NuPharm and Quantum Aseptics Services), which manufacture, procure and supply unlicensed medicines (specials) and special obtains.  In response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment, the division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products.  With an expansive portfolio of products, Quantum is a trusted partner to the majority of large retail pharmacy chains in the UK, as well as pharmaceutical wholesalers, hospitals, independent pharmacies and dispensing doctors.  The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.


Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products) which develop and commercialise niche pharmaceuticals.  This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device).  The division uses the excellent visibility of trends in the UK pharmacy and hospital markets gained through our Specials and Medication Adherence divisions, to allow early identification of the market opportunity to take products from unlicensed (special) status to licensed status.  The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.


Medication Adherence comprises two business units (Biodose® and Biodose Services®) which provide products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies.  It owns Biodose®, the only medication delivery system on the market that accommodates both liquid and solid doses.  Biodose Connect™ takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes.  The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies across the UK and provides the Group with exposure to the homecare and supported living sectors of the care pathway complementing the focus of the remainder of the Group.


For further information, please visit

This information is provided by RNS
The company news service from the London Stock Exchange